June 21, 2017 / 5:22 AM / 6 months ago

BRIEF-Novartis says EMA accepts filing for AMG 334 for preventing migraine

June 21 (Reuters) - Novartis AG

* Novartis achieves important regulatory milestone for amg 334 (erenumab) in migraine prevention with ema filing acceptance

* Novartis says european medicines agency (ema) accepted marketing authorization application for amg 334 (erenumab) for the prevention of migraine Further company coverage: (Reporting By Zurich newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below